EMA Authorised: Cervarix (human papillomavirus1 type 16 L1 protein;human papillomavirus type 18 L1 protein) — GlaxoSmithKline Biologicals S.A.

View source ↗

Summary

Cervarix, a vaccine targeting HPV types 16 and 18, has been authorised by the EMA for use in immunization against papillomavirus infections and associated uteri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillomavirus Infections
• Uterine Cervical Dysplasia

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Status: Authorised. Therapeutic area: Papillomavirus Infections;Uterine Cervical Dysplasia;Immunization. MAH: GlaxoSmithKline Biologicals S.A.. Decision date: 08/07/2026